Figure 2

Luteolin inhibits tumor growth in cMet-overexpressing PDTX models of gastric cancer. a: Changes in tumor volume in Met-GC1 and Met-GC2 models of gastric cancer treated for 30 days with luteolin (10 mg/kg ip daily) or DMSO (as a vehicle control). b: Tumor growth inhibition rates in Met-GC1 and Met-GC2 models of gastric cancer treated with luteolin (10 mg/kg ip daily). c: Changes in mouse body weight in Met-GC1 and Met-GC2 models of gastric cancer treated for 30 days with luteolin (10 mg/kg ip daily) or DMSO (as a vehicle control). Data are presented as the mean ± SD. *P < 0.05 (Student’s t-test).